Medicinal Chemistry Research
References
Kato GJ, Steinberg MH, Gladwin MT (2017) Intravascular hemolysis
and the pathophysiology of sickle cell disease. J Clin Invest
127:750–760
Lanaro C, Franco-Penteado CF, Silva FH, Fertrin KY, Dos Santos JL,
Wade M, Yerigenahally S, De Melo TR, Chin CM, Kutlar A,
Meiler SE, Costa FF (2017) A thalidomide-hydroxyurea hybrid
increases HbF production in sickle cell mice and reduces the
release of proinflammatory cytokines in cultured monocytes. Exp
Hematol 58:35–38
Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers GP (2007) Thalidomide
induces gamma-globin gene expression through increased reac-
tive oxygen species-mediated p38 MAPK signaling and histone
H4 acetylation in adult erythropoiesis. Blood 110:2864–2871
Born GV, Cross MJ (1963) The aggregation of blood platelets. J
Physiol 168:178–195
Cena C, Visentin S, Di Stilo A, Boschi D, Fruttero R, Gasco A (2001)
Studies on agents with mixed NO-dependent and calcium channel
antagonistic vasodilating activities. Pharm Res 18:157–165
Davila J, Manwani D, Vasovic L, Avanzi M, Uehlinger J, Ireland K,
Mitchell WB (2015) A novel inflammatory role for platelets in
sickle cell disease. Platelets 26:726–729
Miyachi H, Azuma A, Ogasawara A, Uchimura E, Watanabe N,
Kobayashi Y, Kato F, Kato M, Hashimoto Y (1997) Novel bio-
logical response modifiers: phthalimides with tumor necrosis
factor-alpha production-regulating activity.
J Med Chem
29:2858–2865
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan
G (1993) Thalidomide exerts its inhibitory action on tumor
necrosis factor alpha by enhancing mRNA degradation. J Exp
Med 177:1675–1680
Mosmann T (1983) Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays. J
Immunol Methods 65:55–63
Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT,
Chen Y, Kaplan G, Stirling DI (1999) Amino-substituted thali-
domide analogs: potent inhibitors of TNF-alpha production.
Bioorg Med Chem Lett 9:1625–1630
Noubouossie D, Key NS, Ataga KI (2016) Coagulation abnormalities
of sickle cell disease: relationship with clinical outcomes and the
effect of disease modifying therapies. Blood Rev 30:245–256
Perrine SP, Pace BS, Faller DV (2014) Targeted fetal hemoglobin
induction for treatment of beta hemoglobinopathies. Hematol
Oncol Clin 28:233–248
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991)
Thalidomide selectively inhibits tumour necrosis factor α pro-
duction by stimulated human monocytes. J Exp Med 173:
699–703
Silva FH, Karakus S, Musicki B, Matsui H, Bivalacqua TJ, Dos Santos
JL, Costa FF, Burnett AL (2016) Beneficial effect of the nitric
oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate
on dysregulated phosphodiesterase 5, NADPH oxidase, and
nitrosative stress in the sickle cell mouse penis: implication for
priapism treatment. J Pharmacol Exp Ther 359:230–237
Sugiharam K, Sugihara T, Mohandas N, Hebbel RP (1992) Throm-
bospondin mediates adherence of CD36 + sickle reticulocytes to
endothelial cells. Blood 80:2634–2642
Dejana E, Callioni A, Quintana A, de Gaetano G (1979) Bleeding time
in laboratory animals. II - A comparison of different assay con-
ditions in rats. Thromb Res 15:191–197
Dos Santos JL, Lanaro C, Chelucci RC, Gambero S, Bosquesi PL,
Reis JS, Lima LM, Cerecetto H, González M, Costa FF, Chung
MC (2012) Design, synthesis, and pharmacological evaluation of
novel hybrid compounds to treat sickle cell disease symptoms.
Part II: furoxan derivatives. J Med Chem 55:7583–7592
Dos Santos JL, Lanaro C, Chin CM (2011) Advances in sickle cell
disease treatment: from drug discovery until the patient mon-
itoring. Cardiovasc Hematol Agents Med Chem 9:113–127
Dos Santos JL, Lanaro C, Lima LM, Gambero S, Franco-Penteado CF,
Alexandre-Moreira MS, Wade M, Yerigenahally S, Kutlar A,
Meiler SE, Costa FF, Chung MC (2011) Design, synthesis, and
pharmacological evaluation of novel hybrid compounds to treat
sickle cell disease symptoms. J Med Chem 54:5811–5819
Dworkis DA, Klings ES, Solovieff N, Li G, Milton JN, Hartley SW,
Melista E, Parente J, Sebastiani P, Steinberg MH, Baldwin CT
(2011) Severe sickle cell anemia is associated with increased plasma
levels of TNF-R1 and VCAM-1. Am J Hematol 86:220–223
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B,
Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D,
Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko
JN, Robitaille N, Segbefia CI, Rees DC, DOVE Investigators
(2016) A multinational trial of Prasugrel for sickle cell vaso-
occlusive events. N Engl J Med 374:625–635
Ingram VM (1957) Gene mutations in human haemoglobin: the che-
mical difference between normal and sickle haemoglobin. Nature
180:326–328
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K,
Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa
FF, Vichinsky EP (2018) Sickle cell disease. Nat Rev Dis Primers
4:18010
Zhang D, Xu C, Manwani D, Frenette PS (2016) Neutrophils, plate-
lets, and inflammatory pathways at the nexus of sickle cell disease
pathophysiology. Blood 127:801–809